drug · small molecule
PMP-1606
Phase 2updated 3mo agoby Premark Pharma GmbH🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for atopic eczema and eczematoid dermatitis and 10 investigational indications.
targets
Peptidyl-prolyl cis-trans isomerase FKBP1A
all catalysts(0)
nothing on the calendar yet
Trials studying PMP-1606
- phase3A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
- phase3A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
- —10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
- phase1A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis
- phase1A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)
- —Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that